TG Therapeutics Announces European Launch of BRIUMVI (Ublituximab-xiiy), Bags a Milestone Payment of $12.5M
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics, Inc. announced the European launch of BRIUMVI for treating relapsing forms of multiple sclerosis, starting in Germany, with plans for further European expansion. The launch triggers a $12.5M milestone payment to TG Therapeutics from its partner, Neuraxpharm Group.
February 26, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics receives a $12.5M milestone payment from Neuraxpharm for the European launch of BRIUMVI, starting in Germany, with further launches planned across Europe.
The European launch of BRIUMVI and the associated milestone payment of $12.5M from Neuraxpharm to TG Therapeutics is a significant positive development. It not only boosts TG Therapeutics' revenue but also marks the expansion of BRIUMVI in a key market. The launch in Germany, followed by other European countries, could lead to increased sales and further milestone payments, positively impacting TGTX's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100